Mitral Valve Plasty During Correction of Combined Mitral-Aortic Valve Diseases

Keywords: combined mitral-aortic defect, aortic valve prosthesis, mitral valve plasty, artificial circulation


The aim. To study reconstructive operations on the mitral valve (MV) combined with aortic valve replacement (AVR) for combined mitral-aortic valve defects (CMAVD).

Materials and methods. The study included 1690 patients with CMAVD who underwent surgical treatment at the National Amosov Institute of Cardiovascular Surgery of the National Academy of Medical Sciences of Ukraine for the period from 01/01/2006 to 01/01/2020. Of these, 429 (23.4%) patients underwent MV reconstruction with AVR.

The following valve-sparing procedures were performed:
– application of annuloplasty ring: 123 (28.7%);
– MV suture annuloplasty: 137 (31.9%);
– open mitral commissurotomy: 47 (11.0%);
– open mitral commissurotomy + leaflet plication: 4 (0.9%);
– application of autopericardial patch on the MV leaflet: 7 (1.6%);
– alfieri procedure (MV bicuspidalization): 34 (7.9%);
– mitral valve debridgment 12: (2.8%);
– plasty with autopericardial patch: 18 (4.2%);
– removal of vegetation from MV structures : 7 (1.6%);
– resection of MV leaflets with addition of suture annuloplasty: 19 (4.4%);
– resection of MV leaflets with addition of an annuloplasty ring: 21 (4.9%).

Results. Fatal complications occurred in 4 cases due to heart failure (n = 2) and multiple organ failure (n = 2). Hospital mortality in AVR with MK plasticity MV plasty was 0.9%, which once again emphasizes the importance of traumatic intervention compared with combined mitral-aortic prosthetics, where mortality is 3 times higher. It decreased from 2.9% (2006–2012, n = 128) to 0.3% (2013–2019, n = 301), which indicates the effectiveness of the method with a significant increase in the number of operated patients.

After correction, MV regurgitation decreased from +2.4 ± 0.3 to +0.4 ± 0.03. Coaptation of the sash Mk MV leaflets after correction was 7.4 ± 0.6 mm.

At the hospital stage there was a decrease in the diastolic peak gradient on the MV from 19.4 ± 4.8 mm Hg to 6.4 ± 0.8 mm Hg. In the remote period, 82.6% of the discharged patients (n = 351) in the period of were followed for 9.3 ± 2.4 years. Better indicators were noted in group of patients with functional class III than those with functional class IV (p <0.05). Fatal outcomes due to thromboembolic complications (n = 29) were caused by the presence of a mechanical aortic prosthesis and partial non-compliance with the protocol of anticoagulant therapy. Unsatisfactory result in the group with changes in the MV was due to the activity of the rheumatic process and progressive heart failure with prolonged atrial fibrillation (n = 37).

The etiology of the defect affected the long-term outcome. The activity of the rheumatic process in patients with functional class IV determined changes in the MV leaflets in the long term and worsened the result.

MV regurgitation increased from +0.08 ± 0.03 (5 years after surgery) to +1.2 ± 0.3 (10 years after surgery). In the long term there was an increase in the diastolic peak gradient on the MV from 9.4 ± 0.4 mm Hg (5 years after surgery) to 13.4 ± 3.2 mm Hg (10 years after surgery). MV replacement was performed in 4 patients 6, 9, 10, 11 years after surgery.

Conclusions. Given the available clinical experience, it is advisable to recommend reconstructive interventions on the MV to correct CMAVD and improve the level of survival and stability of good results.


  1. Bonow R, Braunwald E. Valvular Heart Disease. In: Zipes D, Libby P, Bonow R, Braunwald E, editors. Braunwald’s Heart Disease. 7th edition. Elsevier Saunders; 2005. p. 1572-7.
  2. Zhou YX, Leobon B, Berthoumieu P, Roux D, Glock Y, Mei YQ, et al. Long-term outcomes following repair or replacement in degenerative mitral valve disease. Thorac Cardiovasc Surg. 2010;58(7):415-21.
  3. Pagni S, Ganzel BL, Singh R, Austin EH, Mascio C, Williams ML, et al. Clinical outcome after triple-valve operations in the modern era: are elderly patients at increased surgical risk? Ann Thorac Surg. 2014 Feb;97(2):569-76.
  4. Morimoto H, Tsuchiya K, Nakajima M, Akashi O. Mitral valve repair for anterior leaflet prolapse: surgical techniques review and 16-year follow-up results. J Card Surg. 2008;23(5):426-30.
  5. Seeburger J, Kuntze T, Mohr FW. Gore-tex chordoplasty in degenerative mitral valve repair. Semin Thorac Cardio-vasc Surg. 2007;19(2):111-5.
  6. Leone A, Fortuna D, Gabbieri D, Nicolini F, Contini GA, Pigini F, et al. Triple valve surgery: results from a multicenter experience. J Cardiovasc Med (Hagerstown). 2018 Jul;19(7):382-388.
  7. Davarpasand T, Hosseinsabet A. Triple valve replacement for rheumatic heart disease: short- and mid-term survival in modern era. Interact Cardiovasc Thorac Surg. 2015 Mar;20(3):359-64.
  8. Kumar AS, Talwar S, Saxena A, Singh R, Velayoudam D. Results of mitral valve repair in rheumatic mitral regurgitation. Interact Cardiovasc Thorac Surg. 2006;5(4):356-61.
  9. Popov V, Pukas K, Beshlyaga V, Rybacova, Lazorishinetz V. Risk factors for replacement and plastic procedure in combined mitral-aortic valve disease [abstract]. J Cardiovasc Surg. 2018;59(3 Suppl 2):29.
  10. Talwar S, Mathur A, Choudhary SK, Singh R, Kumar AS. Aortic valve replacement with mitral valve repair compared with combined aortic and mitral valve replacement. Ann Thorac Surg. 2007 Oct;84(4):1219-25.
  11. Seeburger J, Falk V, Borger MA, Passage J, Walther T, Doll N, et al. Chordae replacement versus resection for repair of isolated posterior mitral leaflet prolapse: a egalite. Ann Thorac Surg 2009;87(6):1715-20.
  12. Vohra HA, Whistance RN, Hechadi J, de Kerchove L, Fuller H, Noirhomme P, et al. Long-term outcomes of concomitant aortic and mitral valve repair. J Thorac Cardiovasc Surg. 2014 Aug;148(2):454-60.
How to Cite
Vitovskiy, R., Bolshak, O., Boukarim, V., Bakhovska, Y., & Popov, V. (2020). Mitral Valve Plasty During Correction of Combined Mitral-Aortic Valve Diseases. Ukrainian Journal of Cardiovascular Surgery, (4 (41), 63-68.